Supplementary Table 1.
Risk factors for 30-day mortality after EUS-hepaticogastrostomy for perihilar cholangiocarcinoma
| 30-day mortality after EUS-hepaticogastrostomy | ||||
|---|---|---|---|---|
|
| ||||
| Univariate analysis (OR [95% C.I.) | P | Multivariate analysis (OR [95% C.I.) | P | |
| Gender (male) | NS | NS | - | - |
| Age | 1.16 [1.03-1.31] | 0.02 | 1.23 [1.04-1.45] | 0.02 |
| Study period (2018-2020) | NS | NS | - | - |
| Bismuth-Corlette classification | NS | NS | - | - |
| Distant metastasis | NS | NS | - | - |
| Ascites | 5.25 [0.91-30.2] | 0.06 | NS | NS |
| Unfit for chemotherapy | 12.0 [1.84-78.4] | 0.009 | NS | NS |
| Basal bilirubin levels | NS | NS | - | - |
| Indication for biliary drainage | NS | NS | - | - |
| Clinical success | 0.08 [0.01-0.54] | 0.001 | 0.03 [0.01-0.49] | 0.02 |
| Type of stent | NS | NS | - | - |
| Adverse event | NS | NS | - | - |
| Stent dysfunction | NS | NS | - | - |
| Need for reintervention | NS | NS | - | - |
| Chemotherapy start | 0.15 [0.00-0.41] | <0.001 | NS | NS |
OR: Odd ratio, 95% C.I.: 95% confidence interval, NS: Not statistically significant